Safeguarding Patient Welfare: Who's In Charge?

  title={Safeguarding Patient Welfare: Who's In Charge?},
  author={J. Henney},
  journal={Annals of Internal Medicine},
  • J. Henney
  • Published 2006
  • Medicine
  • Annals of Internal Medicine
Over the course of my career, I have been privileged to serve in a variety of roles, including that of oncologist, principal investigator, study manager, senior academic administrator, Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA), and as board member for 3 Fortune 500 and Global 500 companies (AstraZeneca PLC, 2001 to present; AmerisourceBergen Corporation, 2002 to present; and Cigna Corporation, 2004 to present). I have been regulated and a regulator, and I… Expand
8 Citations
Evaluating Off-Label Uses of Anticancer Drugs: Time for a Change
  • H. Sox
  • Medicine
  • Annals of Internal Medicine
  • 2009
  • 13
  • PDF
Sorrell v. IMS Health: issues and opportunities for informaticians
  • 5
  • PDF
Who needs another journal?
Pharmaceutical promotion to physicians and First Amendment rights.
  • 30
Indication creep: physician beware
  • 22
  • PDF
L'expansion des indications : médecins, attention
  • 2
  • PDF


Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
  • 287
  • Highly Influential
  • PDF
Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach.
  • 48
  • PDF
Off-label prescribing among office-based physicians.
  • 586
  • PDF
New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation.
  • 40
Shalala, 130 F.Supp
  • (D. DC
  • 2001
Advertising and Promotion
  • 369